Nothing Special   »   [go: up one dir, main page]

MX2019003623A - Composiciones y metodos para el tratamiento de afecciones oftalmicas. - Google Patents

Composiciones y metodos para el tratamiento de afecciones oftalmicas.

Info

Publication number
MX2019003623A
MX2019003623A MX2019003623A MX2019003623A MX2019003623A MX 2019003623 A MX2019003623 A MX 2019003623A MX 2019003623 A MX2019003623 A MX 2019003623A MX 2019003623 A MX2019003623 A MX 2019003623A MX 2019003623 A MX2019003623 A MX 2019003623A
Authority
MX
Mexico
Prior art keywords
compositions
methods
ophthalmic conditions
treating ophthalmic
treating
Prior art date
Application number
MX2019003623A
Other languages
English (en)
Inventor
Rigas Basil
Original Assignee
Medicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicon Pharmaceuticals Inc filed Critical Medicon Pharmaceuticals Inc
Publication of MX2019003623A publication Critical patent/MX2019003623A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a composiciones y métodos para tratar afecciones oftálmicas.
MX2019003623A 2016-09-28 2017-09-28 Composiciones y metodos para el tratamiento de afecciones oftalmicas. MX2019003623A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662400955P 2016-09-28 2016-09-28
US201762564595P 2017-09-28 2017-09-28
PCT/US2017/054051 WO2018064354A1 (en) 2016-09-28 2017-09-28 Compositions and methods for treating ophthalmic conditions

Publications (1)

Publication Number Publication Date
MX2019003623A true MX2019003623A (es) 2019-09-23

Family

ID=61760847

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003623A MX2019003623A (es) 2016-09-28 2017-09-28 Composiciones y metodos para el tratamiento de afecciones oftalmicas.

Country Status (7)

Country Link
US (2) US11510931B2 (es)
JP (1) JP7030345B2 (es)
AU (2) AU2017336765B2 (es)
BR (1) BR112019006160A2 (es)
CA (1) CA3038528A1 (es)
MX (1) MX2019003623A (es)
WO (1) WO2018064354A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101321742B (zh) 2005-05-26 2012-08-29 神经元系统公司 用于治疗视网膜疾病的组合物和方法
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
JP6514114B2 (ja) 2013-01-23 2019-05-15 アルデイラ セラピューティクス， インコーポレイテッド 毒性アルデヒド関連疾患および処置
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
JP7082115B2 (ja) 2016-06-02 2022-06-07 エイディーエス セラピューティクス リミテッド ライアビリティ カンパニー 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法
US11510931B2 (en) 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
CA3077033A1 (en) * 2017-09-28 2019-04-04 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
MX2020003425A (es) 2017-10-10 2020-07-29 Aldeyra Therapeutics Inc Tratamiento de trastornos inflamatorios.
WO2020018498A1 (en) * 2018-07-16 2020-01-23 Aldeyra Therapeutics, Inc. Cyclodextrin formulations
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CA3115664A1 (en) * 2018-08-29 2020-03-05 Ocugen, Inc. Ophthalmic compositions and methods of use
EP3856478A4 (en) 2018-09-25 2022-06-08 Aldeyra Therapeutics, Inc. FORMULATIONS FOR THE TREATMENT OF DRY EYE DISEASE
KR102151051B1 (ko) * 2019-01-10 2020-09-02 고려대학교 산학협력단 당뇨병성 백내장 치료 또는 예방용 조성물
JP2022526917A (ja) 2019-03-26 2022-05-27 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CA3146811A1 (en) * 2019-09-10 2021-03-18 Cloudbreak Therapeutics, Llc Methods for alleviating pterygium-associated worry about eye appearance
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
US20230302032A1 (en) * 2020-08-04 2023-09-28 Harrow Ip Llc Antibacterial compositions and methods for fabricating thereof
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
EP4288151A1 (en) 2021-02-03 2023-12-13 ADS Therapeutics LLC Topical ophthalmological compositions
US11213551B1 (en) 2021-04-05 2022-01-04 Korb Research, Llc. Ocular treatment compositions and methods of use thereof
MX2023013855A (es) * 2021-05-24 2023-12-08 Medicon Pharmaceuticals Inc Tratamiento del dolor asociado a la neuropatia periferica inducida por la quimioterapia.
MX2023013853A (es) * 2021-05-24 2023-12-08 Medicon Pharmaceuticals Inc Tratamiento del dolor asociado a la neuropatia diabetica periferica.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4309566A (en) 1979-11-05 1982-01-05 Fmc Corporation Plant regulator
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
CA2166722A1 (en) 1994-05-06 1995-11-16 Manoj L. Maniar Use of vitamin e tocopheryl derivatives in ophthalmic compositions
EP1051167A1 (en) 1998-01-29 2000-11-15 Sepracor, Inc. Pharmaceutical uses of optically pure (-) -bupropion
RU26988U1 (ru) 2002-05-06 2003-01-10 Закрытое акционерное общество "ДУКС-ЛИЗИНГ" Кондуктор для сверления отверстий
US20080153746A1 (en) 2004-04-06 2008-06-26 Transmolecular, Inc. Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers
UA86981C2 (ru) 2004-06-23 2009-06-10 Сирион Терапьютикс, Инк. Применение производных ретинила для лечения офтальмических состояний
US20070299124A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
US20090010850A1 (en) 2007-05-24 2009-01-08 Ousler Iii George W Formulations and methods for treating dry eye
ES2618482T3 (es) 2007-08-10 2017-06-21 Basil Rigas Compuestos antiinflamatorios y usos de los mismos
US20120295979A1 (en) 2011-05-03 2012-11-22 Florida Atlantic University Use of sulindac for protecting retinal pigment epithelial cells against oxidative stress
US20130225529A1 (en) * 2012-02-27 2013-08-29 Basil Rigas Phospho-ester derivatives and uses thereof
CN105658651A (zh) 2012-09-21 2016-06-08 巴兹尔·里格斯 用于治疗炎症相关的病症、疼痛和发热、皮肤病症、癌症及其癌症前期状况的组合物
WO2014167327A1 (en) 2013-04-09 2014-10-16 Cresset Biomolecular Discovery Ltd The treatment of inflammatory disorders
US11510931B2 (en) 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
CA3077033A1 (en) 2017-09-28 2019-04-04 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions

Also Published As

Publication number Publication date
CA3038528A1 (en) 2018-04-05
AU2017336765B2 (en) 2023-06-08
WO2018064354A1 (en) 2018-04-05
JP2019533016A (ja) 2019-11-14
BR112019006160A2 (pt) 2019-06-18
JP7030345B2 (ja) 2022-03-07
AU2023226711A1 (en) 2023-09-21
US20230293557A1 (en) 2023-09-21
AU2017336765A1 (en) 2019-04-18
US11510931B2 (en) 2022-11-29
US20190343848A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2018006239A (es) Composiciones que comprenden cepas bacterianas.
MX2018006398A (es) Composiciones que comprenden cepas bacterianas.
MX2017016529A (es) Composiciones que comprenden cepas bacterianas.
MX2017016564A (es) Composiciones que comprenden cepas bacterianas.
MX2017016398A (es) Composiciones que comprenden cepas bacterianas.
MX2017016560A (es) Composiciones que comprenden cepas bacterianas.
MX2017016525A (es) Composiciones que comprenden cepas bacterianas.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
GB2541571A (en) Pharmaceutical compositions
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MY186271A (en) Ophthalmic compositions and methods of use therefor
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
PH12017501864A1 (en) Compositions and methods for treating autism
EP3687524A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF OPHTHALMIC DISORDERS
PH12017501022A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
PH12017500602A1 (en) Methods for treating ocular conditions
MX2017013729A (es) Deteccion especifica de isoformas de clusterina.